Clostridioides difficile infection: a comprehensive review for primary providers

Cortés, Pedro; Bi, Yan; Stancampiano, Fernando; Valery, Jose R.; Cooper, Jane H.; Harris, Dana M.

doi:10.2478/rjim-2021-0010

Abstract

Clostridioides difficile infection (CDI) is an issue of great concern due to its rising incidence, recurrence, morbidity and impact on healthcare spending. Treatment guidelines have changed in the last few years, and new therapies are being considered. This is a practical review for the primary care practitioner of the latest guidelines for CDI diagnosis, treatment, and emerging therapies.

References

1. BARTLETT JG. Narrative review: the new epidemic of Clostridium difficile-associated enteric disease. Ann Intern Med. 2006;145(10):758–64.10.7326/0003-4819-145-10-200611210-0000817116920
Search in Google Scholar Back to article
2. LAWSON PA., CITRON DM., TYRRELL KL., FINEGOLD SM. Reclassification of Clostridium difficile as Clostridioides difficile (Hall and O’Toole 1935) Prévot 1938. Anaerobe. 2016;40:95–9.10.1016/j.anaerobe.2016.06.00827370902
Search in Google Scholar Back to article
3. LESSA FC., WINSTON LG., MCDONALD LC. Emerging Infections Program CdST. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015;372(24):2369–2370.
Search in Google Scholar Back to article
4. MILLER M., GRAVEL D., MULVEY M., TAYLOR G., BOYD D., SIMOR A., et al. Health care-associated Clostridium difficile infection in Canada: patient age and infecting strain type are highly predictive of severe outcome and mortality. Clin Infect Dis. 2010;50(2):194–201.10.1086/64921320025526
Search in Google Scholar Back to article
5. GUH AY., MU Y., WINSTON LG., JOHNSTON H., OLSON D., FARLEY MM., et al. Trends in U.S. Burden of Clostridioides difficile Infection and Outcomes. N Engl J Med. 2020;382(14):1320–1330.10.1056/NEJMoa1910215786188232242357
Search in Google Scholar Back to article
6. MCDONALD LC., GERDING DN., JOHNSON S., BAKKEN JS., CARROLL KC., COFFIN SE., et al. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) Clin Inf Diseases. 2018;66(7):e1–e48.10.1093/cid/cix1085601898329462280
Search in Google Scholar Back to article
7. THOMAS C., STEVENSON M., RILEY TV. Antibiotics and hospital-acquired Clostridium difficile-associated diarrhoea: a systematic review. J Antimicrob Chemother. 2003;51(6):1339–50.10.1093/jac/dkg25412746372
Search in Google Scholar Back to article
8. WISTROM J., NORRBY SR., MYHRE EB., ERIKSSON S., GRANSTROM G., LAGERGREN., et al. Frequency of antibiotic-associated diarrhoea in 2462 antibiotic-treated hospitalized patients: a prospective study. J Antimicrob Chemother. 2001;47(1):43–50.10.1093/jac/47.1.4311152430
Search in Google Scholar Back to article
9. LOO VG., BOURGAUALT AM., POIRIER L., LAMOTHE F., MICHAUD S., TURGEON N., et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med. 2011;365(18):1693–703.10.1056/NEJMoa101241322047560
Search in Google Scholar Back to article
10. BLISS DZ., JOHNSON S., SAVIK K., CLABOTS CR., WILLARD K., GERDING DN., et al. Acquisition of Clostridium difficile and Clostridium difficile-associated diarrhea in hospitalized patients receiving tube feedings. Ann Intern Med. 1998;129(12):1012–9.10.7326/0003-4819-129-12-199812150-000049867755
Search in Google Scholar Back to article
11. SINGH H., NUGENT Z., YU BN., LIX LM., TARGOWNIK LE., BERNSTEIN CN., et al. Higher Incidence of Clostridium difficile Infection Among Individuals With Inflammatory Bowel Disease. Gastroenterology. 2017;153(2):430–438.10.1053/j.gastro.2017.04.04428479377
Search in Google Scholar Back to article
12. REIGADAS E., ALCALA L., GOMEZ J., MARIN M., MARTIN A., ONORI R., et al. Breakthrough Clostridium difficile Infection in Cirrhotic Patients Receiving Rifaximin. Clin Infect Dis. 2018;66(7):1086–1091.10.1093/cid/cix918
Search in Google Scholar Back to article
13. HU MY., KATCHAR K., KYNE L., MAROO S., TUMMALA S., DREISBACH V., et al. Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection. Gastroenterology. 2009;136(4):1206–14.10.1053/j.gastro.2008.12.038
Search in Google Scholar Back to article
14. D’AGOSTINO RB SR., COLLINS SH., PENCINA KM., KEAN Y., GORBACH S. Risk estimation for recurrent Clostridium difficile infection based on clinical factors. Clin Infect Dis. 2014;58(10);1386–93.10.1093/cid/ciu107
Search in Google Scholar Back to article
15. KYNE L., WARNY M., QAMAR A., KELLY CP. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet. 2001;357(9251):189–93.10.1016/S0140-6736(00)03592-3
Search in Google Scholar Back to article
16. GUPTA SB., MEHTA V., DUBBERKE ER., ZHAO X., DORR MB., GURIS D., et al. Antibodies to Toxin B Are Protective Against Clostridium difficile Infection Recurrence. Clin Infec Dis. 2016;63(6):730–734.10.1093/cid/ciw36427365387
Search in Google Scholar Back to article
17. ABOU CHAKRA CN., MCGEER A., LABBE AC., SIMOR AE., GOLD WL., MULLER MP., et al. Factors Associated With Complications of Clostridium difficile Infection in a Multicenter Prospective Cohort. Clin Infect Dis. 2015;61(12):1781–8.10.1093/cid/civ749465753826338788
Search in Google Scholar Back to article
18. ABRAHAM FM., TALAN DA., KRISHNADASAN A., CITRON DM., PAULICK AL., ANDERSON LJ., et al. Clostridium difficile Infection Among US Emergency Department With Diarrhea and No Vomiting. Ann Emerg Med. 2017;70(1):19–27.10.1016/j.annemergmed.2016.12.01328242058
Search in Google Scholar Back to article
19. SURAWICZ CM., BRANDT LJ., BINION DG., ANANTHAKRISHNAN AN., CURRY SR., GILLIGAN PH., et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol. 2013;108(4):478–98.10.1038/ajg.2013.423439232
Search in Google Scholar Back to article
20. BAUER MP., KUIJPER EJ., VAN DISSEL JT. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). Clin Microbiol Infect. 2009;15(12):1067–79.10.1111/j.1469-0691.2009.03099.x19929973
Search in Google Scholar Back to article
21. DEBAST SB., BAUER MP., KUIJPER EJ. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect. 2014;20 Supple 2:1–26.10.1111/1469-0691.1241824118601
Search in Google Scholar Back to article
22. ABUJAMEL T., CADNUM JL., JURY LA., SUNKESULA VC., KUNDRAPU S., JUMP RL., et al. Defining the vulnerable period of re-establishment of Clostridium-difficile colonization after treatment of C. difficile infection with oral vancomycin or metronidazole. PLoS One. 2013;8(10):e76269.10.1371/journal.pone.0076269
Search in Google Scholar Back to article
23. DOLL M., MARRA AR., APISARNTHANARAK A., AL-MAANI AS., ABBAS S., ROSENTHAL VD. Prevention of Clostridioides difficile in hospitals: A position paper of the International Society for Infectious Diseases. Int J Infect Dis. 2021;102;188–195.10.1016/j.ijid.2020.10.039
Search in Google Scholar Back to article
24. FORRESTER JD., BANAEI N., BUCHNER P., SPAIN DA., STAUDENMAYER KL. Environmental Sampling for Clostridium Difficile on Alcohol-Based Hand Rub Dispensers in an Academic Medical Center. Surg Infect. 2014;15(5):581–4.10.1089/sur.2013.102
Search in Google Scholar Back to article
25. MULLISH BH., MARCHESI JR., THURSZ MR., WILLIAMS HR. Microbiome manipulation with faecal microbiome transplantation as a therapeutic strategy in Clostridium difficile infection. QJM. 2015;108(5):355–9.10.1093/qjmed/hcu182
Search in Google Scholar Back to article
26. CHO JM., PARDI DS., KHANNA S. Update on Treatment of Clostridioides difficile Infection. Mayo Clin Proc. 2020;95(4):758–769.10.1016/j.mayocp.2019.08.006
Search in Google Scholar Back to article
27. KWAK S., CHOI J., HINK T., RESKE KA., BLOUNT K., JONES C., et al. Impact of investigational microbiota therapeutic RBX2660 on the gut microbiome and resistome revealed by a placebo-controlled clinical trial. Microbiome. 2020;8(1):125.10.1186/s40168-020-00907-9
Search in Google Scholar Back to article
28. GERDING DN., MEYER T., LEE C., COHEN SH., MURTHY UK., POIRIER A., et al. Administration of spores of nontoxigenic Clostridium difficile strain M2 for prevention of recurrent C. difficile infection: a randomized clinical trial. JAMA. 2015;313(17):1719–27.
Search in Google Scholar Back to article
29. ALONSO CD., MAHONEY MV. Bezlotoxumab for the prevention of Clostridium difficile infection: a review of current and safety profile. Infect Drug Resist. 2018;12:1–9.10.2147/IDR.S159957
Search in Google Scholar Back to article
30. WILCOX MH., GERDING DN., POXTON IR., KELLY C., NATHAN R., BIRCH T., et al. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection. N Engl J Med. 2017;376(4):305–317.10.1056/NEJMoa1602615
Search in Google Scholar Back to article
31. GERDING DN., KELLY CP., RAHAV G., LEE C., DUBBERKE ER., KUMAR PN., et al. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence. Clin Infect Dis. 2018;67(5):649–656.10.1093/cid/ciy171
Search in Google Scholar Back to article
32. VICKERS RJ., TILLOTSON GS., NATHAN R., HAZAN S., PULLMAN J., LUCASTI C., et al. Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority study. Lancet Infect Dis. 2017;17(7):735–744.10.1016/S1473-3099(17)30235-9
Search in Google Scholar Back to article
33. GANETSKY A., HAN JH., HUGHES ME., BABUSHOK DV., FREY NV. GILL SI., et al. Oral Vancomycin Prophylaxis Is Highly Effective in Preventing Clostridium difficile Infection in Allogeneic Hematopoietic Cell Transplant Recipients. Clin Infect Dis. 2019;68(12):2003–2009.10.1093/cid/ciy822654173130256954
Search in Google Scholar Back to article
34. SENOH M., IWAKI M., YAMAMOTO A., KATO H. FUKUDA T. SHIBAYAMA K. Development of vaccine for Clostridium difficile infection using membrane fraction of nontoxigenic Clostridium difficile. Microb Pathog. 2018;123:42–46.10.1016/j.micpath.2018.06.03929959036
Search in Google Scholar Back to article
35. ZHANG C., JIN K., XIAO Y., CHENG Y., HUANG Z., WANG S., et al. Potent monoclonal antibodies against Clostridium difficile toxin A elicited by DNA immunization. Hum Vaccin Immunother. 2013;9(10):2157–64.10.4161/hv.25656390640023851482
Search in Google Scholar Back to article
36. HOPKINS RJ., WILSON RB. Treatment of recurrent Clostridium diffiicle colitis: a narrative review. Gastroenterol Rep. 2018;6(1):21–28.10.1093/gastro/gox041580640029479439
Search in Google Scholar Back to article
37. OOIJEVAAR RE., VAN VEURDEN YH., TERVEER EM., GOORHUIS A., BAUER MP., KELLER JJ., et al. Update on treatment algorithms for Clostridium difficile infection. Clin Micribiol Infect. 2018;24(5):452–462.10.1016/j.cmi.2017.12.02229309934
Search in Google Scholar Back to article

Clostridioides difficile infection: a comprehensive review for primary providers

Abstract

Paradigm

My account